Sökning: WFRF:(Zou Chang)
> (2020-2024) >
Establishing a Urin...
Establishing a Urine-Based Biomarker Assay for Prostate Cancer Risk Stratification
-
- Guo, Jinan (författare)
- Jinan University,Shenzhen People's Hospital
-
- Liu, Dale (författare)
- Jinan University,Shenzhen People's Hospital
-
- Zhang, Xuhui (författare)
- Beijing Institute of Basic Medical Sciences
-
visa fler...
-
- Johnson, Heather (författare)
- Olympia Diagnostics, Inc.
-
- Feng, Xiaoyan (författare)
- Beijing Institute of Basic Medical Sciences
-
- Zhang, Heqiu (författare)
- Beijing Institute of Basic Medical Sciences
-
- Wu, Alan H. B. (författare)
- San Francisco General Hospital
-
- Chen, Lingwu (författare)
- First Affiliated Hospital of Sun Yat-sen University
-
- Fang, Jiequn (författare)
- Shenzhen People's Hospital,Jinan University
-
- Xiao, Zhangang (författare)
- Southwest Medical University
-
- Xiao, Kefeng (författare)
- Shenzhen People's Hospital,Jinan University
-
- Persson, Jenny L., Professor (författare)
- Umeå University,Lund University,Lunds universitet,Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten),Division of Experimental Cancer Research, Department of Translational Medicine, Lund University, Malmö, Sweden,Jenny Persson,Experimentell cancerforskning, Malmö,Forskargrupper vid Lunds universitet,Experimental Cancer Research, Malmö,Lund University Research Groups
-
- Zou, Chang (författare)
- Shenzhen People's Hospital,Jinan University
-
visa färre...
-
(creator_code:org_t)
- 2020-12-10
- 2020
- Engelska.
-
Ingår i: Frontiers in Cell and Developmental Biology. - Swiss : Frontiers Media S.A.. - 2296-634X. ; 8
- Relaterad länk:
-
https://doi.org/10.3...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://www.frontier...
-
http://dx.doi.org/10... (free)
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- One of the major features of prostate cancer (PCa) is its heterogeneity, which often leads to uncertainty in cancer diagnostics and unnecessary biopsies as well as overtreatment of the disease. Novel non-invasive tests using multiple biomarkers that can identify clinically high-risk cancer patients for immediate treatment and monitor patients with low-risk cancer for active surveillance are urgently needed to improve treatment decision and cancer management. In this study, we identified 14 promising biomarkers associated with PCa and tested the performance of these biomarkers on tissue specimens and pre-biopsy urinary sediments. These biomarkers showed differential gene expression in higher- and lower-risk PCa. The 14-Gene Panel urine test (PMP22, GOLM1, LMTK2, EZH2, GSTP1, PCA3, VEGFA, CST3, PTEN, PIP5K1A, CDK1, TMPRSS2, ANXA3, and CCND1) was assessed in two independent prospective and retrospective urine study cohorts and showed high diagnostic accuracy to identify higher-risk PCa patients with the need for treatment and lower-risk patients for surveillance. The AUC was 0.897 (95% CI 0.939–0.855) in the prospective cohort (n = 202), and AUC was 0.899 (95% CI 0.964–0.834) in the retrospective cohort (n = 97). In contrast, serum PSA and Gleason score had much lower accuracy in the same 202 patient cohorts [AUC was 0.821 (95% CI 0.879–0.763) for PSA and 0.860 (95% CI 0.910–0.810) for Gleason score]. In addition, the 14-Gene Panel was more accurate at risk stratification in a subgroup of patients with Gleason scores 6 and 7 in the prospective cohort (n = 132) with AUC of 0.923 (95% CI 0.968–0.878) than PSA [AUC of 0.773 (95% CI 0.852–0.794)] and Gleason score [AUC of 0.776 (95% CI 0.854–0.698)]. Furthermore, the 14-Gene Panel was found to be able to accurately distinguish PCa from benign prostate with AUC of 0.854 (95% CI 0.892–0.816) in a prospective urine study cohort (n = 393), while PSA had lower accuracy with AUC of 0.652 (95% CI 0.706–0.598). Taken together, the 14-Gene Panel urine test represents a promising non-invasive tool for detection of higher-risk PCa to aid treatment decision and lower-risk PCa for active surveillance.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- urine-based biomarker
- Gene Panel
- prostate cancer
- Gleason score
- cancer risk stratification
- cancer risk stratification
- Gene Panel
- Gleason score
- prostate cancer
- urine-based biomarker
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Guo, Jinan
-
Liu, Dale
-
Zhang, Xuhui
-
Johnson, Heather
-
Feng, Xiaoyan
-
Zhang, Heqiu
-
visa fler...
-
Wu, Alan H. B.
-
Chen, Lingwu
-
Fang, Jiequn
-
Xiao, Zhangang
-
Xiao, Kefeng
-
Persson, Jenny L ...
-
Zou, Chang
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Frontiers in Cel ...
- Av lärosätet
-
Umeå universitet
-
Lunds universitet